Literature DB >> 29404962

Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival.

Jacob C Kinskey1, Yaping N Tu1, Wei Lue Tong1, John M Yavorski1, George Blanck2,3.   

Abstract

We assessed pancreatic cancer, lymphocyte infiltrates with a computational genomics approach. We took advantage of tumor-specimen exome files available from the cancer genome atlas to mine T- and B-cell immune receptor recombinations, using highly efficient, scripted algorithms established in several previous reports. Surprisingly, the results indicated that pancreatic cancer exomes represent one of the highest level yields for immune receptor recombinations, significantly higher than two comparison cancers used in this study, head and neck and bladder cancer. In particular, pancreatic cancer exomes have very large numbers of immunoglobulin light chain recombinations, both with regard to number of samples characterized by recovery of such recombinations and with regard to numbers of recombination reads per sample. These results were consistent with B-cell biomarkers, which emphasized the Th2 nature of the pancreatic lymphocyte infiltrate. The tumor specimen exomes with B-cell immune receptor recombination reads represented a dramatically poor outcome, a result not detected with either the head and neck or bladder cancer datasets. The results presented here support the potential value of immunotherapies designed to engineer a Th2 to Th1 shift in treating certain forms of pancreatic cancer.

Entities:  

Keywords:  B-cell infiltrates; Immunoglobulin gene recombinations; Pancreatic cancer exomes; Survival rates; The cancer genome atlas

Year:  2018        PMID: 29404962      PMCID: PMC6008263          DOI: 10.1007/s12307-018-0205-5

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  27 in total

1.  Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Authors:  Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

2.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

3.  Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA.

Authors:  Shanitra N Butler; George Blanck
Journal:  Cell Tissue Res       Date:  2015-08-21       Impact factor: 5.249

4.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Authors:  Leore T Geller; Michal Barzily-Rokni; Tal Danino; Oliver H Jonas; Noam Shental; Deborah Nejman; Nancy Gavert; Yaara Zwang; Zachary A Cooper; Kevin Shee; Christoph A Thaiss; Alexandre Reuben; Jonathan Livny; Roi Avraham; Dennie T Frederick; Matteo Ligorio; Kelly Chatman; Stephen E Johnston; Carrie M Mosher; Alexander Brandis; Garold Fuks; Candice Gurbatri; Vancheswaran Gopalakrishnan; Michael Kim; Mark W Hurd; Matthew Katz; Jason Fleming; Anirban Maitra; David A Smith; Matt Skalak; Jeffrey Bu; Monia Michaud; Sunia A Trauger; Iris Barshack; Talia Golan; Judith Sandbank; Keith T Flaherty; Anna Mandinova; Wendy S Garrett; Sarah P Thayer; Cristina R Ferrone; Curtis Huttenhower; Sangeeta N Bhatia; Dirk Gevers; Jennifer A Wargo; Todd R Golub; Ravid Straussman
Journal:  Science       Date:  2017-09-15       Impact factor: 47.728

Review 5.  Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.

Authors:  Brant A Inman; Thomas A Longo; Sundhar Ramalingam; Michael R Harrison
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

6.  Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA-seq data.

Authors:  Bo Li; Taiwen Li; Binbin Wang; Ruoxu Dou; Jian Zhang; Jun S Liu; X Shirley Liu
Journal:  Nat Genet       Date:  2017-03-30       Impact factor: 38.330

7.  Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen W Behrman; Edgar Ben-Josef; Al B Benson; Ephraim S Casper; Steven J Cohen; Brian Czito; Joshua D I Ellenhorn; William G Hawkins; Joseph Herman; John P Hoffman; Andrew Ko; Srinadh Komanduri; Albert Koong; Wen Wee Ma; Mokenge P Malafa; Nipun B Merchant; Sean J Mulvihill; Peter Muscarella; Eric K Nakakura; Jorge Obando; Martha B Pitman; Aaron R Sasson; Anitra Tally; Sarah P Thayer; Samuel Whiting; Robert A Wolff; Brian M Wolpin; Deborah A Freedman-Cass; Dorothy A Shead
Journal:  J Natl Compr Canc Netw       Date:  2012-06-01       Impact factor: 11.908

Review 8.  The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.

Authors:  Kim Margolin
Journal:  Curr Treat Options Oncol       Date:  2016-09

9.  Profiling tissue-resident T cell repertoires by RNA sequencing.

Authors:  Scott D Brown; Lisa A Raeburn; Robert A Holt
Journal:  Genome Med       Date:  2015-11-30       Impact factor: 11.117

Review 10.  Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.

Authors:  Shilpa Gupta; David Gill; Austin Poole; Neeraj Agarwal
Journal:  Cancers (Basel)       Date:  2017-01-27       Impact factor: 6.639

View more
  3 in total

1.  A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.

Authors:  Boris I Chobrutskiy; Michelle Yeagley; Andrea Diviney; Saif Zaman; Etienne C Gozlan; Price Tipping; Darush M Koohestani; Andrea M Roca; George Blanck
Journal:  Immunology       Date:  2020-01-21       Impact factor: 7.397

2.  Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade.

Authors:  Boris I Chobrutskiy; Saif Zaman; Wei Lue Tong; Andrea Diviney; George Blanck
Journal:  J Neurooncol       Date:  2018-10-31       Impact factor: 4.130

3.  Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells.

Authors:  Etienne C Gozlan; Boris I Chobrutskiy; Saif Zaman; Michelle Yeagley; George Blanck
Journal:  J Mol Neurosci       Date:  2021-03-05       Impact factor: 3.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.